NASDAQ · Biotechnology

Astria Therapeutics, Inc. (ATXS) Stock

$12.58 +0.00% NASDAQ: ATXS Healthcare

Astria Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 2008.

Valuation

MetricValue
Price$12.58
Market Cap$718.13M
P/E Ratio-7.40
P/B Ratio3.13
P/S Ratio1017.18
EPS (TTM)$-1.68
52-Week High$13.29
52-Week Low$3.56
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-37.70%
ROA-36.20%
ROCE-43.05%
Gross Margin100.00%
Operating Margin—
Net Margin—
Debt/Equity0.02
Current Ratio10.78

Annual Financials (USD)

Metric20202021202220232024
Revenue$0$0$0$0$0
Operating Profit$-37.0M$-195.0M$-54.0M$-83.0M$-112.0M
Net Profit$-37.0M$-195.0M$-52.0M$-73.0M$-94.0M
EPS$-12.20$-24.58$-3.55$-2.42$-1.68
Op Margin—————

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$47.0M$128.0M$231.0M$255.0M$342.0M
Total Liabilities$7.0M$5.0M$9.0M$12.0M$23.0M
Cash$25.0M$87.0M$21.0M$176.0M$60.0M
Borrowings$1.0M$0$1.0M$0$5.0M

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-32.0M$-30.0M$-44.0M$-68.0M$-81.0M
Investing Cash Flow$6.0M$-13.0M$-167.0M$135.0M$-192.0M
Financing Cash Flow$0$0$0$0$5.0M
Net Cash Flow$15.0M$62.0M$-66.0M$155.0M$-116.0M
Free Cash Flow$-33.0M$-30.0M$-44.0M$-68.0M$-82.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.90
EV / EBITDA-6.36
FCF Yield-14.34%
Quick Ratio10.78
Interest Coverage0.00
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARVN $8.02 -3.43% -6.94 $517.14M 0.00%
AVBP $30.84 -0.55% -8.82 $1.44B 0.00%
DAWNDay One Biopharmaceuticals, Inc. $21.53 +0.00% -20.70 $2.22B 0.00%
DNA $8.07 -0.19% -1.30 $527.50M 0.00%
ERAS $17.72 -2.42% -23.45 $6.15B 0.00%

About Astria Therapeutics, Inc.

Astria Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 2008. The firm specializes in identifying, advancing, and bringing to market treatments for uncommon and specialized allergic and immunological disorders across the United States. Its leading experimental drug, STAR-0215, is a monoclonal antibody that targets and inhibits plasma kallikrein. This candidate is presently undergoing preclinical development to address hereditary angioedema. The company adopted its current name, Astria Therapeutics, Inc., in September 2021, having previously operated as Catabasis Pharmaceuticals, Inc.

Astria Therapeutics, Inc. is headquartered in US.

Astria Therapeutics, Inc. (ATXS) stock trades at $12.58 with a market capitalization of $718.13M. The stock is valued at a price-to-earnings (P/E) ratio of -7.40, price-to-book of 3.13, price-to-sales of 1017.18. Over the past 52 weeks the stock has ranged between $3.56 and $13.29, and currently trades 5.3% below its 52-week high.

On profitability, Astria Therapeutics, Inc. generates a return on equity (ROE) of -37.70%, return on capital employed of -43.05%.

Official website: www.astriatx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides